

Active substances set

Search phrase: brentuximab vedotin

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Hodgkin's disease

Brentuximab vedotin

Brentuximab Vedotin is indicated for adult patients with previously untreated CD30+ Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD). Brentuximab Vedotin is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT). Brentuximab Vedotin is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): 1. following ASCT, or 2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.

 **REIMBURSEMENT
WITH RESTRICTIONS**

 **ESMO**

non-Hodgkin lymphoma

Brentuximab vedotin

Brentuximab Vedotin in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL). Brentuximab Vedotin is indicated for the treatment of adult patients with relapsed or refractory sALCL. Brentuximab Vedotin is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.

 **REIMBURSEMENT
WITH RESTRICTIONS**

 **ESMO**